Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus rituximab vs lenalidomide plus rituximab in relapsed/refractory marginal zone lymphoma
CTR20233094Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in marginal zone B-cell lymphoma (MZL), sponsored by Innovent Biologics. Started Dec 2023; status: active.
02
Drugs
orelabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20233094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233094.